Jonathan G Pol, Sergio A Acuna, Beta Yadollahi, Nan Tang, Kyle B Stephenson, Matthew J Atherton, David Hanwell, Alexander El-Warrak, Alyssa Goldstein, Badru Moloo, Patricia V Turner, Roberto Lopez, Sandra LaFrance, Carole Evelegh, Galina Denisova, Robin Parsons, Jamie Millar, Gautier Stoll, Chantal G Martin, Julia Pomoransky, Caroline J Breitbach, Jonathan L Bramson, John C Bell, Yonghong Wan, David F Stojdl, Brian D Lichty, J Andrea McCart
Multiple immunotherapeutics have been approved for cancer patients, however advanced solid tumors are frequently refractory to treatment. We evaluated the safety and immunogenicity of a vaccination approach with multimodal oncolytic potential in non-human primates (NHP) ( Macaca fascicularis ). Primates received a replication-deficient adenoviral prime, boosted by the oncolytic Maraba MG1 rhabdovirus. Both vectors expressed the human MAGE-A3. No severe adverse events were observed. Boosting with MG1-MAGEA3 induced an expansion of hMAGE-A3-specific CD4+ and CD8+ T-cells with the latter peaking at remarkable levels and persisting for several months...
2019: Oncoimmunology